Inhibition of glycogen synthase kinase 3 beta ameliorates liver ischemia reperfusion injury by way of an interleukin-10-mediated immune regulatory mechanism

Authors

  • Feng Ren,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    2. Artificial Liver Center, Beijing You'an Hospital, Affiliated to Capital Medical University, Beijing, China
    Search for more papers by this author
  • Zhongping Duan,

    1. Artificial Liver Center, Beijing You'an Hospital, Affiliated to Capital Medical University, Beijing, China
    Search for more papers by this author
  • Qiao Cheng,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Search for more papers by this author
  • Xiuda Shen,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Search for more papers by this author
  • Feng Gao,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Search for more papers by this author
  • Li Bai,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    2. Artificial Liver Center, Beijing You'an Hospital, Affiliated to Capital Medical University, Beijing, China
    Search for more papers by this author
  • Jun Liu,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Search for more papers by this author
  • Ronald W. Busuttil,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Search for more papers by this author
  • Jerzy W. Kupiec-Weglinski,

    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Search for more papers by this author
  • Yuan Zhai

    Corresponding author
    1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    • Dumont-UCLA Transplant Center 77-120 CHS, 10833 Le Conte Ave., Los Angeles, CA 90095
    Search for more papers by this author
    • fax: (310) 267-2367


  • Potential conflict of interest: Nothing to report.

  • Supported by NIH Grants RO1 DK083408 (to Y.Z.), DK062357 (to J.W.K.W.), The Dumont Research Foundation, and the Major State Basic Research Development Program of China 2007CB512801 (to F.R., Z.D., and L.B.), the Key Projects in the National Science & Technology Program of Eleventh Five-year Plan 2008ZX10002-005-3 (to Z.D.), the National High Technology Research and Development Program of China 2006AA02A410 (to Z.D.).

Abstract

The ubiquitous serine/threonine kinase glycogen synthase kinase 3 beta (Gsk3β) differentially regulates macrophage Toll-like receptor (TLR)-triggered pro- and anti-inflammatory cytokine programs. This study was designed to determine the in vivo role and therapeutic potential of Gsk3β modulation in tissue inflammation and injury in a murine model of liver partial warm ischemia/reperfusion injury (IRI). As a constitutively activated liver kinase, Gsk3β became quickly inactivated (phosphorylated) following IR. The active Gsk3β, however, was essential for the development of IRI pathology, as administration of its specific inhibitor, SB216763, ameliorated the hepatocellular damage, evidenced by reduced serum alanine aminotransferase (sALT) levels and well-preserved liver architecture compared with controls. The liver protective effect of Gsk3β inhibition was dependent on an immune regulatory mechanism, rather than direct cytoprotection via mitochondria permeability transition pores (MPTP). Indeed: (1) coadministration of SB216763 and atractyloside (MPTP opener) failed to abrogate a local cytoprotective Gsk3β inhibition effect; (2) SB216763 selectively inhibited IR-triggered liver pro-inflammatory, but spared interleukin (IL)-10, gene induction programs; and (3) IL-10 neutralization restored liver inflammation and IRI in SB216763-treated mice. Gsk3β inactivation by IR was a self-regulatory mechanism in liver homeostasis, critically dependent on phosphoinositide 3 (PI3)-kinase activation, as administration of a PI3 kinase inhibitor, wortmannin, reduced Gsk3 phosphorylation and augmented liver damage. In vitro, IL-10 was critical for the suppression of pro-inflammatory gene programs by Gsk3 inhibition in bone marrow-derived macrophages in response to TLR4 stimulation. Conclusion: Our novel findings document the key immune regulatory function of Gsk3β signaling in the pathophysiology of liver IRI, and provide a rationale to target Gsk3β as a refined therapeutic strategy to ameliorate liver IRI. (HEPATOLOGY 2011;)

Ischemia and reperfusion injury (IRI) is a common clinical problem associated with liver transplantation, partial hepatic resection, or trauma. Although IRI significantly impacts both acute liver failure/graft rejection, as well as chronic liver dysfunction,1-4 no effective therapy is available to prevent or treat the clinical syndrome. The pathogenesis of IRI is a two-stage process consisting of the initial cellular damage due to ischemia, followed by reperfusion-initiated inflammation-induced hepatocellular damage. Recently, host innate Toll-like receptor 4 (TLR4) activation by endogenous ligands has been identified as the key trigger in the liver immune response against IR.5-9 As cell surface TLR4 ligation activates multiple intracellular signaling pathways10, 11 leading to the induction of pro- and anti-inflammatory gene programs, our better appreciation of their regulatory mechanisms should identify novel therapeutic targets to selectively alleviate pro- while sparing or promoting anti-inflammatory immune responses and ultimately ameliorate tissue damage. Recent studies have revealed that glycogen synthase kinase 3β (Gsk3β) may represent such a target. Indeed, inhibition of Gsk3β in vitro significantly increased interleukin (IL)-10 production while suppressing release of pro-inflammatory cytokines in macrophages stimulated with TLR ligands. TLR activation leads to Gsk3β phosphorylation by the phosphoinositide 3 (PI3) kinase-Akt pathway. The resultant increase of 3′-5′-cyclic adenosine monophosphate (cAMP) response element-binding (CREB) but decrease of nuclear factor kappa B (NF-κB) activity diminish the expression of pro-inflammatory genes, such as IL-12, tumor necrosis factor alpha (TNF-α), and IL-1β, while augmenting the expression of anti-inflammatory IL-10.12In vivo, Gsk3β inhibitors effectively protected mice from endotoxin shock.12 These data suggest the therapeutic potential of Gsk3β inhibition and warrant further confirmation in clinically relevant animal inflammatory disease models.

Gsk3, a ubiquitously expressed serine/threonine kinase, was initially found to regulate glycogen synthesis.13, 14 There are two highly homologous Gsk3α and Gsk3β isoforms. Gsk3β, constitutively active (in dephosphorylated form) in resting cells, has a broad range of substrates regulating cell activation, differentiation, and survival. In heart IRI models, Gsk3β inactivation represents the convergence point for multiple cytoprotective signaling pathways.15 Gsk3β regulates the induction of the mitochondrial permeability transition pore (MPTP), a key step in triggering mitochondria-mediated cell death, which constitutes the critical IRI effector pathway. Gsk3 inhibition has been tested successfully as a cardioprotection strategy in myocardial infarction.16-18 However, whether Gsk3 inhibition can protect hepatocytes from IR-induced cell death has yet to be determined.

As IR activates TLR4 signaling and triggers pro-inflammatory response in vivo, we need to determine whether IR does indeed activate the PI3 kinase-Akt-Gsk3β pathway. Furthermore, questions of whether Gsk3β may function to regulate liver immune response and IRI are of high significance to further define the disease pathogenesis and explore putative therapeutic strategies. There are potential drawbacks of Gsk3β inhibition in liver IR. It may increase macrophage interferon beta (IFN-β) production in response to TLR4 stimulation.19 Because type 1 IFN and its downstream gene product CXCL10 are key pro-inflammatory mediators in liver IRI,20 it becomes questionable as to whether Gsk3β inhibition will truly blunt the liver pro-inflammatory program. In addition, Gsk3β genetic deletion results in embryonic lethality due to the severe liver degeneration during development,21 and its inhibition increases hepatocyte apoptosis against TNF-α.22 Thus, Gsk3β inhibition may exert multifaceted functions in the liver during IR. It remains an open question as to whether or not Gsk3β inhibition will indeed ameliorate liver IRI cascade.

Abbreviations

cAMP, 3′-5′-cyclic adenosine monophosphate; CREB, cAMP response element-binding; Gsk3β, glycogen synthase kinase 3 beta; IL, interleukin; IRI, ischemia/reperfusion injury; MPO, myeloperoxidase; MPTP, mitochondria permeability transition pores; PI3, phosphoinositide 3; sALT, serum alanine aminotransferase; TNF-α, tumor necrosis factor alpha; TLR4, Toll-like receptor 4.

Materials and Methods

Animals.

Male wildtype (WT; C57BL/6) mice (8-12 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). Animals were housed in the UCLA animal facility under specific pathogen-free conditions and received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Mouse Warm Hepatic IRI Model.

Liver partial warm IR was performed as described.23 In brief, an atraumatic clip was used to interrupt the arterial and portal venous blood supply to the cephalad liver lobes for 90 minutes (or 60 minutes in PI3 kinase inhibition experiments). Sham WT controls underwent the same procedure, but without vascular occlusion. To inhibit Gsk3β or PI3 kinase activity, mice were treated with a single dose of SB216763 (25 μg/g, Sigma, St. Louis, MO) or wortmannin (1 μg/g, Sigma) dissolved in dimethyl sulfoxide (DMSO)/phosphate-buffered zsaline (PBS), or atractyloside (5 μg/g, Enzo Life Sciences, Plymouth Meeting, PA) dissolved in PBS, intraperitoneally 2 hours or 1 hour prior to the onset of liver ischemia, respectively. Anti-IL-10 antibody (Ab) (0.5 mg/mouse, Clone JES5-2A5, Bio-Express, West Lebanon, NH) was administered, intraperitoneally, 1 hour prior to the liver ischemia. Mice were sacrificed at various timepoints of reperfusion; liver and serum samples were collected for future analysis.

Hepatocellular Damage Assay.

Serum alanine aminotransferase (sALT) levels, an indicator of hepatocellular injury, were measured with an autoanalyzer (ANTECH Diagnostics, Los Angeles, CA).

Liver Histology.

Liver sections were cut into 5-μm sections and stained with hematoxylin and eosin (H&E). Histological severity of IRI was graded using Suzuki's criteria on a scale from 0 to 4.24 No necrosis, congestion/centrilobular ballooning is given a score of 0, whereas severe congestion/degeneration and >60% lobular necrosis is given a value of 4.

MPO Assay.

To detect neutrophil activity, myeloperoxidase (MPO), an enzyme specific for polymorphonuclear neutrophils, was measured in the liver. Briefly, the frozen tissue was thawed and placed in iced 0.5% hexadecyltrimethyl-ammonium bromide and 50 mmol potassium phosphate buffer solution (pH = 5.0). Each sample was homogenized and centrifuged at 15,000 rpm for 15 minutes at 4°C. Supernatants were mixed with hydrogen peroxide-sodium acetate and tetramethyl-benzidine solutions. The change in absorbance was measured by spectrophotometry at 655 nm. One unit of MPO activity was defined as the quantity of enzyme degrading 1 μmol peroxide/min at 25°C/g of tissue.

Cell Cultures.

Mouse macrophage RAW264.7 (ATCC, Manassas, VA) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). Lipopolysaccharide (LPS) (10 ng/mL, Invivogen, San Diego, CA) was used to activate cells. Antimycin A (10 μg/mL, Sigma) was used to inhibit cell oxidation and ATP synthesis. SB 216763 (10 μM/mL) was used to inhibit Gsk3β.

Murine bone marrow-derived macrophages (BMM) were differentiated from bone marrow from 6 to 10-week-old C57B/6 mice by culturing in 1× DMEM, 10% fetal bovine serum, 1% penicillin/streptomycin, and 20% L929 conditioned medium for 6 days. The cell purity was 94%-99% CD11b+.

Quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR).

Two and a half μg of RNA was reverse-transcribed into complementary DNA (cDNA) using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA). Quantitative PCR was performed using the DNA Engine with Chromo 4 Detector (MJ Research, Waltham, MA). In a final reaction volume of 25 μL, the following were added: 1× SuperMix (Platinum SYBR Green qPCR Kit, Invitrogen), cDNA, and 0.5 mM of each primer. Amplification conditions were: 50°C (2 minutes), 95°C (5 minutes), followed by 50 cycles of 95°C (15 seconds), 60°C (30 seconds). Primers used to amplify a specific mouse gene fragments have been described.25

Western Blots.

Protein was extracted from liver tissue with ice-cold lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 10% glycerol, 137 mM sodium chloride, 20 mM Tris, pH 7.4). Proteins (20 μg) were subjected to 12% SDS polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis and transferred to PVDF nitrocellulose membrane. Antibodies against phosphorylated and total Gsk3β, extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and p38 mitogen-activated protein (MAP) kinase proteins, as well as β-actin (Cell Signaling Technology, Santa Cruz, CA) were used for western blot analysis. Membranes were probed with primary antibody (1:1,000) in 10 mL blocking buffer overnight at 4°C. After washing, membranes were further probed with appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (1:2,000) in 10 mL of blocking buffer for 1 hour at room temperature. SuperSignal West Pico Chemiluminescent Substrates (Thermo Fisher Scientific, Rockford, IL) were used for chemoluminescence development.

Statistical Analysis.

Results are shown as mean ± standard deviation (SD). Statistical analyses were performed using unpaired Student's t test with P < 0.05 (two-tailed) considered significant.

Results

Gsk3β Activation/Inactivation Profile in Liver IR.

We first determined whether IR stimulation triggers Gsk3β phosphorylation/dephosphorylation in mouse livers subjected to 90 minutes of warm ischemia, followed by various lengths of reperfusion. Compared with sham controls, the phosphorylated Gsk3β (at serine 9) level was slightly reduced by ischemia itself (time 0), and then rapidly increased at reperfusion and remained phosphorylated throughout the reperfusion phase (1-6 hours) (Fig. 1). As total Gsk3β levels were equal at all timepoints, these results indicate that the constitutively active Gsk3β in the liver was inactivated by the IR insult and sustained inactive thereafter. Gsk3β activation profile was distinct from that of MAP kinases, which were only transiently activated by IR, but quickly decreased to baseline by 4 hours postreperfusion (Fig. 1). The phosphorylation of tyrosine 216 on Gsk3β was not detected, nor was the phosphorylation of Gsk3α in IR livers (data not shown). Thus, liver IR triggers Gsk3β phosphorylation on serine 9, which is sustained throughout the reperfusion period.

Figure 1.

Liver ischemia and reperfusion triggers Gsk3β phosphorylation. Liver samples were harvested from B6 mice that were either sham-operated or subjected to 90 minutes of hepatic warm ischemia, followed by various lengths of reperfusion (0, 1, 4 hours). The phosphorylated (serine 9) and total Gsk3β levels, along with phosphorylated MAP kinases including JNK, Erk, and p38, and β-actin were measured by western blots. Representative of two experiments is shown.

Active Gsk3β Is Critical for the Development of Liver IRI.

To address the functional significance of the constitutively active Gsk3β, we treated mice with a Gsk3β-specific chemical inhibitor, SB216763, prior to the onset of ischemia. The inhibition of liver Gsk3 activity in vivo was confirmed by the reduced phosphorylation level of glycogen synthase, the substrate of Gsk3β (Fig. 2A). As compared with vehicle-treated controls, livers in animals receiving SB216763 suffered less severe IRI, evidenced by significantly lower sALT levels (Fig. 2B, 7,709 ± 1,689 versus 2,946 ± 513; P = 0.0053), better preserved liver architecture by histology (Fig. 2C) and Suzuki grading (Fig. 2D, 3.6 ± 0.24 versus 2.2 ± 0.40 n = 5-6/group, P < 0.05). In parallel, pretreatment with SB216763 suppressed neutrophil activation, measured by MPO activity (Fig. 2E, 5.73 ± 1.50 versus 3.30 ± 0.54; P < 0.05), and diminished the induction of TNF-α, IL-1β, IL-6, and CXCL10 in IR-livers (Fig. 2F). It has been shown that IR-induced IL-12 and IL-10 are transient and occur early in postreperfusion.25 To determine the impact of Gsk3 inhibition on the induction of these two genes by IR, livers were harvested at 1 hour post-reperfusion from separate groups of mice. Although Gsk3 inhibition slightly reduced IL-10 expression in IR-livers, its impact on IL-12p40 gene induction was much more pronounced, leading to a significant increase in the IL-10/IL-12 ratio in the SB216763-treated group as compared with controls (Fig. 2G). Thus, active Gsk3β was essential for the pro-inflammatory immune response and the development of liver IRI. Its inhibition preferentially suppressed pro-inflammatory gene program, whereas IL-10 induction was relatively spared.

Figure 2.

Gsk3 inhibition by SB216763 ameliorates liver IRI in B6 mice. (A) Mice were treated with vehicle (DMSO) or SB216763. Liver samples, harvested 24 hours later, were subjected to western blot analysis of phosphorylated glycogen synthases. (B) Mice were sham-operated or subjected to 90 minutes warm ischemia followed by 1-hour or 6-hour reperfusion. Recipients were treated with vehicle (DMSO) or SB216763. Group averages of sALT levels at 6 hours were measured and plotted (n = 5-12/group). (C) Representative liver histology (H&E staining at 6 hours). (C) Group averages of liver Suzuki scores (6 hours). (E) Liver MPO levels at 6 hours. (F) Expression levels of inflammatory TNF-α, CXCL10, IL-1β, and IL-6 at 6 hours. (G) IL-12p40 and IL-10 at 1 hour and 6 hours of reperfusion (n = 4-5/group). *P < 0.05.

IL-10-Dependent Mechanism, but Not Direct Cytoprotection, Mediates Gsk3 Inhibition-Mediated Liver Protection.

To analyze liver protection mechanisms of Gsk3 inhibition, we differentiated between direct cytoprotection (by way of inhibition of MPTP) and immune regulation. Mice underwent adjunctive treatment with astractyloside (Atr), an MTPT opener, or anti-IL-10 Ab together with Gsk3 inhibitor (SB216763), followed by liver IR insult. In contrast to its protective effects in the heart,26, 27 treatment with Atr did not affect the beneficial effect of Gsk3 inhibition in the liver. However, concomitant neutralization of IL-10 readily recreated liver damage. Hence, sALT levels in the Atr plus SB216763 treatment group were significantly lower as compared to those in Atr-treated or vehicle-treated groups (Fig. 3A, Atr/SB: 917 ± 104 versus Atr: 3,994 ± 739, P = 0.001; versus Ctl: 6,239 ± 725, P < 0.001). In marked contrast, sALT levels in SB plus anti-IL-10 Ab treatment group were significantly higher than in the SB216763 monotherapy group, and became comparable with those in controls (Fig. 3B, SB/anti-IL-10: 3,683 ± 720.3 versus SB: 769.0 ± 203.7; P = 0.02; versus Ctl: 5,691 ± 1,205, P = ns). The histology evaluation showed the hepatocellular damage, corresponding with sALT levels in the respective animal groups (Fig. 3C). Consequently, IL-10 neutralization restored liver proinflammatory immune response against IR in SB-treated mice, as evidenced by increased TNF-α, IL-1β, IL-6, and CXCL10 expression (Fig. 3D). Thus, the liver protective mechanism of Gsk3 inhibition depends on IL-10-mediated immune regulation rather than the direct cytoprotection by way of mitochondria.

Figure 3.

Liver protection against IRI following Gsk3 inhibition is independent of MPTP, but dependent on an IL-10-mediated immune regulation. Groups of B6 mice were treated with vehicle, Atr, or SB216763 (SB), or SB + Atr or SB +anti-IL-10 Ab, and then subjected to 90 minutes of ischemia, followed by 6 hours reperfusion, as described in Materials and Methods. (A,B) Group averages of sALT levels were measured and plotted. (C) Representative liver histology (H&E staining). (D) Group averages of liver proinflammatory gene (TNF-α, CXCL10, IL-1β, and IL-6) expression levels. (C) n = 3-6/group, *P < 0.05.

PI3 Kinase-Dependent Gsk3 Phosphorylation Regulates Liver IRI.

As Gsk3β phosphorylation occurs spontaneously during liver IR, we then addressed the functional significance of its inactivation. As the PI3 kinase-Akt pathway has been shown in vitro to regulate Gsk3β phosphorylation downstream of TLR4 activation,12 we utilized wortmannin, an irreversible PI3 kinase-specific inhibitor, to test whether or not Gsk3β phosphorylation is PI3 kinase-dependent, and, if so, what is its pathophysiology role in liver IRI. Indeed, livers in wortmannin-treated mice were characterized by significantly lower levels of phosphorylated Gsk3β after IR (Fig. 4A) and suffered more severe injury at 6 hours of reperfusion as compared with vehicle-treated controls. This was most pronounced in the 60-minute liver ischemia setting, with the hepatocellular damage less severe than that recorded after 90 minutes of ischemia (Fig. 4B, sALT Ctl: 1,323 ± 295.7 versus WM: 2,775 ± 492.5, n = 5, P < 0.05; and Fig. 4C, liver histology). To confirm that Gsk3β inactivation functioned downstream of PI3 kinase activation, SB216763 and wortmannin were administered in concert prior to the ischemia insult. Gsk3 inhibition remained hepatocytoprotective against IRI in the presence of PI3 kinase inhibition (Fig. 4D, sALT: Ctl, 7,825 ± 583.9 versus SB, 3,511 ± 809.0; P < 0.01; WM, 8,863 ± 826.9 versus SB/WM, 3,069 ± 741.7; P < 0.01). Thus, PI3 kinase-dependent Gsk3β phosphorylation serves as a self-regulatory mechanism of liver homeostasis to limit the excessive IR-triggered tissue damage.

Figure 4.

PI3 kinase activation is responsible for Gsk3β phosphorylation and its inhibition deteriorates liver IRI. Groups of B6 mice were treated with SB216763 (SB), wortmannin (WM), or both or vehicle at 1-2 hours prior to the liver ischemia insult, as described in Materials and Methods. Liver samples were harvested at 6 hours post-reperfusion. Proteins were analyzed by western blots with Abs against phosphorylated or total Gsk3β and β-actin. Sixty minutes ischemia time was used to show the effect of PI3 kinase inhibition in liver IRI. Average sALT levels in different experimental groups were plotted. Representative liver histology (H&E staining) is shown. To establish the functional relationship between PI3 kinase and Gsk3β, SB was administered 2 hours and WM 1 hour prior to the ischemia insult. Serum ALT levels were measured at 6 hours of reperfusion.

Gsk3β Regulates Macrophage TLR4 Response by both Direct and Indirect Mechanisms.

It has been well established that TLR4 activation is the key step in liver inflammatory immune response against IR.5, 9 To investigate the cellular mechanism of our in vivo findings, we analyzed the effects of Gsk3 inhibition in macrophage response to TLR4 stimulation in vitro. Bone marrow-derived macrophages were stimulated with LPS in the absence or presence of SB216763. As shown in Fig. 5A, Gsk3 inhibition significantly reduced IL-12p40 and IL-1β, but increased IL-10 gene induction at 1 hour of culture. In contrast, the induction of TNF-α, IL-6, and CXCL10 were unaffected at this early timepoint. By 6 hours, whereas the IL-12p40 expression remained lower, levels of TNF-α, IL-6, IL-1β, and CXCL10 all became significantly reduced. IL-10 levels were comparable between the two groups. Gsk3 inhibition did not alter LPS-induced MAP kinase activation, as the phosphorylation kinetics of JNK, Erk, and p38 were similar in control and SB-treated macrophage cultures (Fig. 5B). The disparities between IL-12/IL-10 and TNF-α/CXCL10 genes at the timepoints regulated by the Gsk3 inhibition indicated a possible difference in their regulatory mechanisms, i.e., the early regulated genes were the primary targets of Gsk3, whereas the later ones were regulated by the primary gene products. To test whether IL-10 may represent such a primary gene regulating the late inhibition of TNF-α/CXCL10 induction, we added anti-IL-10 Ab in SB216763-treated macrophage cultures. Indeed, LPS-induced TNF-α/CXCL10 levels at 6 hours, which remained diminished by Gsk3 inhibitor alone, became restored (or even enhanced) after adjunctive anti-IL-10 Ab and SB216763 (Fig. 5C). Interestingly, anti-IL-10 Ab restored otherwise suppressed IL-12p40 gene induction by SB216763.

Figure 5.

Gsk3 inhibition regulates TLR4 response in vitro. BMMs were stimulated with LPS for 1 hour or 6 hours in the absence or presence of SB216763. Gene induction profiles were measured by qRT-PCR, as described in Materials and Methods. Average target gene/HPRT ratios for each experimental group were plotted. *P < 0.05 between LPS and SB/LPS groups. BMMs were also harvested after 15 minutes, 30 minutes, 1 hour, or 2 hours stimulation with LPS with or without SB216763. Total cell lysates were analyzed for phosphorylated Gsk3β, JNK, Erk, and p38 MAP kinases, as well as total Gsk3β and β-actin protein levels by western blots. BMMs were stimulated with LPS for 6 hours with or without SB216763 in combination with anti-IL-10 Abs. Group averages of target gene/HPRT gene expression ratios were plotted. *P < 0.05 between SB/LPS and SB/aIL-10/LPS groups. Representative results of at least two separate experiments are shown.

Thus, Gsk3 inhibition regulates macrophage TLR4 response by directly down-regulating the pro-inflammatory IL-12 gene, yet up-regulating the induction of immune regulatory IL-10, which, in turn, further suppresses the pro-inflammatory gene expression programs.

Discussion

Although Gsk3β has been shown to regulate macrophage cytokine production and hepatocyte apoptosis,12, 21 its role in liver IRI cascade, an inflammation-mediated hepatocellular injury process, has not been explored. Our current study demonstrates that liver IR triggered Gsk3β phosphorylation, and the constitutively active Gsk3β was required for the activation of local pro-inflammatory response and the development of hepatocellular damage. Inhibition of Gsk3β protected livers against IRI by down-regulating pro-inflammatory IL-12 and selectively sparing immune regulatory IL-10, resulting in broader suppression of pro-inflammatory gene programs, including TNF-α and CXCL10. Interestingly, IL-10 neutralization recreated liver IRI, stressing the importance of IL-10 immune regulatory mechanism in cytoprotection rendered by Gsk3 inhibition.

Targeting Gsk3 has been proven an effective cardioprotective strategy.16 Unlike pre-conditioning, which triggers Gsk3β phosphorylation, reperfusion with Gsk3 inhibitors, added prior to or even post-ischemia, reduced cell death.17, 18 However, it was also shown that Gsk3 inactivation was not absolutely required for ischemia pre- and post-conditioning.28 Despite controversial in vivo data, the mechanistic basis of these studies was the finding that inhibition of Gsk3β in cardiomyocytes delayed the opening of MPTP in the inner membrane, which protects cells from the intrinsic cell death pathway. The MPTP-triggered cell death was closely associated with IRI development.15 Along the same lines of cytoprotection, Gsk3 inhibition was also shown to protect kidneys and brains from IRI pathology,29-31 as well as livers from drug-induced toxicity.32 Our in vitro hepatocyte culture data are consistent with the positive regulatory role of Gsk3 in stress-induced cell death pathway (data not shown). The liver protective effect of Gsk3 inhibition in vivo does not depend on its suppression of MPTP, as atractyloside, an MPTP opener, did not abolish the effect of SB216763 in our liver IR model. Furthermore, Gsk3 inhibition by SB216763 did not sensitize hepatocytes to TNF-α-induced cell death in vitro (data not shown).

Our results show that the immune regulatory function of Gsk3 inhibition is critical for its beneficial effects in vivo, as IL-10 neutralization not only restored liver pro-inflammatory phenotype, but also dictated the severity of hepatocellular damage. In vivo, SB216763-facilitated Gsk3 inhibition protects mice from endotoxin shock,12 in association with the suppression of pro-inflammatory IL-12, IL-6, IFN-γ and the increase of immune regulatory IL-10. Our study provides further evidence that the suppression of the pro-inflammatory program by Gsk3 inhibitor both in vitro and in vivo was mediated, at least partially, by an IL-10 autocrine mechanism. In macrophage cultures, Gsk3 inhibition selectively suppressed, as early as at 1 hour, LPS-induced IL-12p40 and IL-1β, but not TNF-α, IL-6. A broader suppression of pro-inflammatory cytokines occurred only late (6 hours) and was IL-10-dependent. Importantly, an IL-10-dependent autocrine mechanism was involved in the regulation of CXCL10 by Gsk3 inhibition in response to TLR4 stimulation. CXCL10 is one of the key components of type I IFN pathway downstream of TLR4, both of which are essential in the pathogenesis of liver IRI.9, 20, 25 It has been shown that TLR4-stimulated IFN-β production, unlike other proinflammatory genes, is negatively regulated by Gsk3β.19 We demonstrate that although CXCL10 expression by BMM was not altered by SB216763 at early timepoints, it was down-regulated later on as compared with controls. Thus, although CXCL10 induction by TLR4 signaling is not directly down-regulated by Gsk3 inhibition, it can be suppressed by IL-10, which is readily up-regulated by SB216763.

The phosphorylation of Gsk3β downstream of TLR4 is mediated by the PI3 kinase-Akt pathway.12, 33 Indeed, it is known that PI3K/Akt activation protects hearts and brains from IRI pathology.34-37 Our findings imply that PI3 kinase activation was responsible for Gsk3β phosphorylation in IR-livers, and that PI3 kinase-Gsk3β signaling was a self-regulatory mechanism preventing the excessive IR-hepatocellular damage. It is interesting to note that PI3 kinase inhibition by wortmannin exerted the most profound effect when liver IRI was relatively mild, i.e., induced by 60 minutes rather than by 90 minutes of warm ischemia. This indicates the functional limit of liver self-protective mechanisms that fails after the extended warm ischemia time. Gsk3 inhibition protected livers despite PI3 kinase inhibition, confirming the functional relationship between the two kinases in IRI regulatory pathways. As PI3 kinase is upstream of Gsk3β, targeting the latter may have certain advantages as compared with that of PI3 kinase in terms of both specificity and limited toxicity. Importantly, several potent and specific Gsk3β small molecule inhibitors have been recently tested in preclinical diabetic and Alzheimer's disease models.13, 33

In summary, Gsk3β inhibition represents a potent and safe strategy to ameliorate liver IRI pathology. This approach may provide not only the direct cytoprotection means against stress-induced cell death, but also exert immune modulation to reduce local inflammation. Further preclinical studies with Gsk3β chemical inhibitors are warranted to pave the way for the development of a clinically applicable therapeutic strategy against organ IRI.

Ancillary